ACET Stock Overview
A clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Adicet Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.92 |
| 52 Week High | US$3.77 |
| 52 Week Low | US$0.81 |
| Beta | 1.62 |
| 1 Month Change | 1.80% |
| 3 Month Change | -31.63% |
| 1 Year Change | -44.81% |
| 3 Year Change | -94.07% |
| 5 Year Change | n/a |
| Change since IPO | -94.05% |
Recent News & Updates
Recent updates
Is Adicet Bio (NASDAQ:ACET) In A Good Position To Deliver On Growth Plans?
Jul 12
Adicet Bio: Microcap With A High Risk To Reward Ratio
May 23Adicet Bio, Inc. (NASDAQ:ACET) Shares Could Be 50% Below Their Intrinsic Value Estimate
Feb 01Is Adicet Bio (NASDAQ:ACET) In A Good Position To Invest In Growth?
Dec 07Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?
Aug 07Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans
Apr 20Here's Why We're Not Too Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Situation
Dec 20Healthcare focused investment fund RA Capital takes passive stake in Adicet Bio
Oct 17Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 25%?
Oct 04Downgrade: Here's How Analysts See Adicet Bio, Inc. (NASDAQ:ACET) Performing In The Near Term
Aug 16Adicet Bio: A First Take
Jul 22Adicet Bio (NASDAQ:ACET) Is In A Good Position To Deliver On Growth Plans
Jul 07Results: Adicet Bio, Inc. Confounded Analyst Expectations With A Surprise Profit
May 15We're Not Very Worried About Adicet Bio's (NASDAQ:ACET) Cash Burn Rate
Mar 18Adicet Bio: Gamma Delta 1 CAR-T Technology And A Takeover Candidate
Feb 09Shareholder Returns
| ACET | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.1% | -3.3% | -0.4% |
| 1Y | -44.8% | -2.7% | 24.8% |
Return vs Industry: ACET underperformed the US Biotechs industry which returned -1.9% over the past year.
Return vs Market: ACET underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| ACET volatility | |
|---|---|
| ACET Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ACET has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ACET's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 143 | Chen Schor | www.adicetbio.com |
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Adicet Bio, Inc. Fundamentals Summary
| ACET fundamental statistics | |
|---|---|
| Market cap | US$75.50m |
| Earnings (TTM) | -US$117.88m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs ACET overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACET income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$117.88m |
| Earnings | -US$117.88m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.43 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ACET perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 17:36 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Adicet Bio, Inc. is covered by 11 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Justin Zelin | B. Riley Securities, Inc. |
| John Newman | Canaccord Genuity |
| Yatin Suneja | Guggenheim Securities, LLC |